A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma

Acta Oncologica

Volumn 50, Issue 4, 2011, Pages 589-590

  Farid, Mohamad ^a   Yau, Ying Wei ^a   Tay, Kevin ^a   Quek, Richard ^a   Tao, Miriam ^a   Koo, Ghee Chong ^a   Loong, Susan ^a   Lim, Soon Thye ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BORTEZOMIB; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; OXALIPLATIN;

ADULT; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CASE REPORT; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; LETTER; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR BIOPSY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEOXYCYTIDINE; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, EXTRANODAL NK-T-CELL; LYMPHOMA, T-CELL; ORGANOPLATINUM COMPOUNDS; PYRAZINES; TREATMENT OUTCOME;

EID: 79955601094     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.516272     Document Type: Letter

References (11)

1. ST Lim, Siew WH, Quek R, LC Lim, SP Yap, Loong EL, et al. Comparative analysis of extranodal NK/T cell lymphoma and peripheral T cell lymphoma: Significant differences in clinical characteristics and prognosis. Eur J Haematol 2008;80:55-60 (Pubitemid 350265229)
2. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally natural killer cells and inhibition of P-glycoprotein function by cyclosporine A and its analogue, PSC833. Blood 1999;93: 599-606. (Pubitemid 29035741)
3. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-Asparaginase and etoposide (SMILE) chemotherapy for advanced stage, relapsed or refractory extranodal natural killer (NK)/T cell lymphoma and leukemia. Cancer Sci 2008;99:1016-20. (Pubitemid 351997606)
4. Loong SL, Hwang JS, Lim ST, Yap SP, Tao M, Chong TW, et al. An Epstein Barr Virus positive natural killer lymphoma xenograft derived for drug testing. Leuk Lymphoma 2008; 49:1161-7. (Pubitemid 351943263)
5. GC Koo, W Esa, ST Lim, SY Tan, S Loong. Evaluation of the efficacy of selected chemotherapeutic and immunotherapeutic drugs in NK/T non-Hodgkin' s lymphoma xenograft model. Poster 023. BIT Life Sciences' 2nd Annual World Cancer Congress 2009, Beijing, China.
6. Foss å A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non- Hodgkin' s lymphoma. J Clin Oncol 1999;17:3786-92.
7. Savage DG, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT, et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000;11:595-7. (Pubitemid 30431383)
8. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic and phase I studies of Gemcitabine. Semin Oncol 1997;24(2 Suppl 7):S7-2-S7-7.
9. Hagemeister FB, Diehl V. The role of ifosfamide in cytoreduction, stem cell mobilization and high dose therapy in relapsed/refractory malignant lymphomas. Eur J Haematol Suppl 2001;64:1-2. (Pubitemid 32589042)
10. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, et al. Phase II study of oxaliplatin in patients with recurrent or refractory non Hodgkin' s lymphoma. Cancer 2005;104:781-7. (Pubitemid 41113678)
11. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2' ,2' -difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999;44:117-23. (Pubitemid 29297057)